Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

BACKGROUND: Patients with advanced renal cell carcinoma with sarcomatoid features (sRCC) have a poor prognosis and limited therapeutic options. First-line nivolumab plus ipilimumab (NIVO+IPI) provided efficacy benefits over sunitinib (SUN) in patients with intermediate/poor-risk sRCC at 42 months mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rini, Brian I, Signoretti, Sabina, Choueiri, Toni K, McDermott, David F, Motzer, Robert J, George, Saby, Powles, Thomas, Donskov, Frede, Tykodi, Scott S, Pal, Sumanta K, Gupta, Saurabh, Lee, Chung-Wei, Jiang, Ruiyun, Tannir, Nizar M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791431/
https://www.ncbi.nlm.nih.gov/pubmed/36549781
http://dx.doi.org/10.1136/jitc-2022-005445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791431/
https://www.ncbi.nlm.nih.gov/pubmed/36549781
http://dx.doi.org/10.1136/jitc-2022-005445

Ejemplares similares